Order Article Reprints

Iinuma K, Yamada T, Kameyama K, Taniguchi T, Kawada K, Ishida T, Nagai S, Enomoto T, Ueda S, Takagi K, et al. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. Cancers. 2023; 15(3):947. https://doi.org/10.3390/cancers15030947

Iinuma, Koji, Toyohiro Yamada, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Shingo Nagai, Torai Enomoto, Shota Ueda, Kimiaki Takagi, and et al. 2023. "The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study" Cancers 15, no. 3: 947. https://doi.org/10.3390/cancers15030947

Iinuma, K., Yamada, T., Kameyama, K., Taniguchi, T., Kawada, K., Ishida, T., Nagai, S., Enomoto, T., Ueda, S., Takagi, K., Kawase, M., Takeuchi, S., Kawase, K., Kato, D., Takai, M., Nakane, K., & Koie, T. (2023). The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. Cancers, 15(3), 947. https://doi.org/10.3390/cancers15030947